SUN-P061: Effects of L-Carnitine Supplementation on Body Composition in Patients with Nonalcoholic Steatohepatitis

Amiri-Moghadam, S.; Nematy, Mohsen; Eghtesadi, Shahryar; Khalili, Mohammad Reza; Mojarrad, Malihe Zarrati; Jazayeri, Shima; Vosooghinia, Hassan; Khosravi, Afra; Salehi, Mina; Beheshti-Namdar, A.; Hakkak, A. Mehdizadeh

doi:10.1016/s0261-5614(17)30566-6

Cited by 6 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results were inconsistent with a recent study conducted by Amiri-Moghadam, et al who found weight loss in diabetics with administration of Lcarnitine therapy in a randomized double blind placebo-controlled clinical trial, while our study shows preventive effects 24 of L-carnitine from weight loss. This deviation of the results from our study might be due to long duration of study for 3 months with calorie restricted diet.…”

Section: Anti-hyperglycemic and Anti-oxidative Effects Of L-carnitinecontrasting

confidence: 99%

Anti-Hyperglycemic and Anti-Oxidative Effects of L-Carnitine Administration in Alloxan Induced Diabetic Albino Wistar Rats

Talpur

Meghji

Uqaili

et al. 2019

KMUJ

View full text Add to dashboard Cite

OBJECTIVE:To evaluate anti-hyperglycemic and anti-oxidative effects of Lcarnitine in alloxan induced diabetic albino wistar rats. METHODS:This quasi-experimental study was conducted at Isra University, Hyderabad from June 2017 to August 2017. Thirty-six albino wistar male rats were equally divided into 3 groups (n=12/group); group A (control), group B (alloxan 150mg/kg intraperitoneally) and group C (alloxan 150mg/kg intraperitoneally + L-carnitine 500mg/kg orally for 21 days). Diabetes was induced in group B and C by single intraperitoneal dose of alloxan 150mg/kg body weight and rats having blood glucose >200mg/dl were labeled as diabetic rats and included in study. Biochemical (blood glucose, serum insulin and glutathione peroxidase) and histopathological analysis of pancreas was performed in all three experimental groups. RESULTS:Post-experimental body weight in groups A, B and C were noted as 249.58±6.63, 199.08±12.18, 210.58±5.14 grams respectively. The fasting blood glucose in groups A, B and C were noted as 104.58±7.05, 221.25±8.22, 110.17±12.85 mg/dl respectively (P<0.001). Serum insulin in groups A, B and C was noted as 1.45±0.083, 0.31±0.16, 1.74±0.23 ηg/ml respectively (P<0.001). Glutathione peroxidase levels in groups A, B and C were noted as 1.45±0.17, 0.93±0.11, 1.74±0.17 ηg/ml respectively (P<0.001). Histopathology of pancreas showed reduction in size (mean islet diameter 157±1.5 µm) and number of islets of Langerhans in diabetic rats, while Lcarnitine treated rats have shown compensatory increase in size of islets of Langerhans (mean islet diameter 210±6.3 µm). CONCLUSION: L-carnitine therapy is a potent anti-hyperglycemic and antioxidative regimen capable of reducing blood glucose and increasing plasma antioxidant levels.

show abstract

Section: Anti-hyperglycemic and Anti-oxidative Effects Of L-carnitinecontrasting

confidence: 99%

Anti-Hyperglycemic and Anti-Oxidative Effects of L-Carnitine Administration in Alloxan Induced Diabetic Albino Wistar Rats

Talpur

Meghji

Uqaili

et al. 2019

KMUJ

View full text Add to dashboard Cite

show abstract

“…The review included 508 participants from nine studies in meta-analyses, and detailed information of the included studies is summarized in Table 1. Five of the studies were conducted in Iran [14][15][16][17][18], and two in Italy [11,19]. The other trials were conducted in Japan [20] and China [21].…”

Section: Characteristics Of the Included Rct Studiesmentioning

confidence: 99%

“…The other trials were conducted in Japan [20] and China [21]. The studies were performed in subjects with diabetes mellitus [11,14,21], non-alcoholic steatohepatitis [14,15,19], and knee osteoarthritis [16,17] and in those undergoing hemodialysis [18,20]. The mean age of the subjects was at least 41.6 years in each study.…”

Section: Characteristics Of the Included Rct Studiesmentioning

confidence: 99%

“…The duration of treatment in the studies was between 8 and 24 weeks, and 12 weeks was the most common duration used for interventions. Six RCTs used L-carnitine alone [14,[16][17][18]20,21]; one RCT used L-carnitine in combination with calorie restriction [11]; and two RCTs used a combination of L-carnitine, calorie restriction, and exercise [15,19]. The daily dose of L-carnitine used for supplementation ranged from 0.75 to 3 g/day, and 2 g/day was the most common dose used for intervention.…”

Section: Characteristics Of the Included Rct Studiesmentioning

confidence: 99%

“…Although all the included trials reported "randomly allocating" participants, only seven studies reported generating random numbers by using a computer-generated randomization schedule, a random number table, envelopes, random block, or centralized randomization [11,14,[17][18][19][20][21]. Two studies described allocation concealment [15,16]. Eight studies reported the dropout rate [11,14,[16][17][18][19][20][21], but the remaining study was unclear about the dropout rate [15].…”

Section: Risk Of Bias In the Included Rct Studiesmentioning

confidence: 99%

See 2 more Smart Citations

L-Carnitine’s Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2020

View full text Add to dashboard Cite

A systematic review and meta-analysis of randomized controlled trials (RCTs) was carried out to assess L-carnitine supplements’ influence on the biomarkers of metabolic syndrome (MetSyn). PubMed, EMBASE, Cochrane library, and CINAHL were used to collect RCT studies published prior to February 2020. RCT studies were included if they had at least one of the following biomarker outcome measurements: waist circumference (WC), blood pressure (BP), fasting blood sugar (FBS), triglyceride (TG), or high density lipoprotein-cholesterol (HDLc). Nine of twenty studies with adequate methodological quality were included in this meta-analysis. The dose of L-carnitine supplementation administered varied between 0.75 and 3 g/day for durations of 8–24 weeks. L-carnitine supplementation significantly reduced WC and systolic BP (SBP), with no significant effects on FBS, TG, and HDLc. We found that L-carnitine supplementation at a dose of more than 1 g/d significantly reduced FBS and TG and increased HDLc. In conclusion, L-carnitine supplementation is correlated with a significant reduction of WC and BP. A dose of 1–3 g/d could improve the biomarkers of MetSyn by reducing FBS and TG and increasing HDLc.

show abstract

Effect of Dietary Intervention, with or without Cointerventions, on Inflammatory Markers in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Hall¹,

George²,

Tierney³

et al. 2023

Advances in Nutrition

View full text Add to dashboard Cite

SUN-P061: Effects of L-Carnitine Supplementation on Body Composition in Patients with Nonalcoholic Steatohepatitis

Cited by 6 publications

References 0 publications

Anti-Hyperglycemic and Anti-Oxidative Effects of L-Carnitine Administration in Alloxan Induced Diabetic Albino Wistar Rats

Anti-Hyperglycemic and Anti-Oxidative Effects of L-Carnitine Administration in Alloxan Induced Diabetic Albino Wistar Rats

L-Carnitine’s Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Effect of Dietary Intervention, with or without Cointerventions, on Inflammatory Markers in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About